Other OTC - Delayed Quote USD

Innovent Biologics, Inc. (IVBXF)

5.0000 +0.1100 (+2.25%)
At close: April 26 at 3:06 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for IVBXF

Recent News: IVBXF

View More
Innovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting

Innovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting
PR Newswire 2 days ago
Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer (CMO)

Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer (CMO)
PR Newswire 11 days ago
Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting

Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting
PR Newswire 19 days ago
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status

Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status
PR Newswire 25 days ago
Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy

Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
PR Newswire last month
Health Care Roundup: Market Talk

Health Care Roundup: Market Talk
The Wall Street Journal last month
Innovent Announces 2023 Annual Results and Business Updates

Innovent Announces 2023 Annual Results and Business Updates
PR Newswire last month
Innovent Announces Primary Endpoint Met in the Second Phase 2 Clinical Trial of IBI302 (anti-VEGF/complement) in Treating Neovascular Age-related Macular Degeneration (nAMD)

Innovent Announces Primary Endpoint Met in the Second Phase 2 Clinical Trial of IBI302 (anti-VEGF/complement) in Treating Neovascular Age-related Macular Degeneration (nAMD)
PR Newswire last month
Innovent released the results of two clinical studies of IBI311 (an anti-IGF-1R monoclonal antibody) in oral presentations at the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024

Innovent released the results of two clinical studies of IBI311 (an anti-IGF-1R monoclonal antibody) in oral presentations at the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024
PR Newswire last month
Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer

Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
PR Newswire last month
Innovent Announces First Participant Dosed in a Phase I Study of IBI3002 (an anti-IL-4Rα/TSLP bispecific antibody) in Australia

Innovent Announces First Participant Dosed in a Phase I Study of IBI3002 (an anti-IL-4Rα/TSLP bispecific antibody) in Australia
PR Newswire last month
Innovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPA

Innovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPA
PR Newswire 2 months ago
View More

Related Tickers

SIGY Sigyn Therapeutics, Inc.
6.34
+10.26%
 
BRCTF BioArctic AB (publ)
17.75
0.00%
 
NBIO Nascent Biotech, Inc.
0.0999
0.00%
 
IMUC EOM Pharmaceuticals Holdings, Inc.
0.1979
0.00%
 
ATBPF Antibe Therapeutics Inc.
0.2156
0.00%
 
WXIBF WuXi Biologics (Cayman) Inc.
1.6800
+2.13%
 
CDT Conduit Pharmaceuticals Inc.
3.1700
+0.32%
 
INBX Inhibrx, Inc.
34.06
-0.09%
 
OBIO Orchestra BioMed Holdings, Inc.
4.3900
-1.13%
 
9688.HK Zai Lab Limited
12.620
-0.16%